BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
8.89 ^CNY	+1.95%		-7.01%	-25.79%

05-06	Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	CI
04-26	Biocytogen Pharmaceuticals' Loss Narrows in 2023	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	05-06	CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023	04-26	MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	03-26	AQ
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	03-25	CI
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	02-19	CI
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	01-24	AQ
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	01-23	CI
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	01-09	AQ
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug	01-08	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	01-08	CI
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	12-28	AQ
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	12-27	CI
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	12-20	AQ
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences	12-20	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	12-19	CI
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	12-19	AQ
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates	12-18	MT
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics	12-18	CI
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company	12-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Summary

Filters